Hanmi Pharmaceutical Company Limited
Clinical trials sponsored by Hanmi Pharmaceutical Company Limited, explained in plain language.
A South Korean pharmaceutical company developing drugs and biologics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug HM15275 enters Mid-Stage trial Results expected Jan 2027 (estimated)
- New obesity drug HM17321 enters first human safety trials Results expected Mar 2027 (estimated)
- New drug combo aims to shrink Hard-to-Treat tumors Results expected Aug 2027 (estimated)
-
New blood pressure drug HCP1803-4 faces final test
Disease control Not yet recruitingThis phase 3 trial tests whether a new drug called HCP1803-4 can safely lower blood pressure in adults with essential hypertension. Participants are randomly assigned to receive either the new drug or a control drug. The study measures changes in sitting blood pressure over time …
Phase 3 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Healthy volunteers needed to test how two drug versions behave in the body
Knowledge-focused Not yet recruitingThis early-stage trial will enroll 60 healthy adults to compare two drug formulations: an orally disintegrating tablet (HIP2503) and a standard tablet (HCP1306). The goal is to see how each is absorbed and processed by the body, and to check for safety. Participants will take a s…
Phase 1 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC